Showing results (51-60 of 99) with videos related to
Sort By:
Pageof 10
Gynecologic Oncology|May 9, 2006
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancerGilbert Spizzo, Philip Went, Stephan Dirnhofer, et al.Cancer Immunology, Immunotherapy : CII|February 21, 2007
The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody constructChristian Brandl, Cornelia Haas, Sandrine d'Argouges, et al.Nature Cell Biology|January 13, 2009
Nuclear signalling by tumour-associated antigen EpCAMDorothea Maetzel, Sabine Denzel, Brigitte Mack, et al.Oncoimmunology|March 6, 2023
Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumorsJian Ding, Sarah Guyette, Brett Schrand, et al.Mabs|December 9, 2014
CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomasMichael D Oberst, Stacy Fuhrmann, Kathy Mulgrew, et al.Cancer Immunology, Immunotherapy : CII|July 3, 2008
Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humansMaria Amann, Matthias Friedrich, Petra Lutterbuese, et al.Experimental Hematology & Oncology|May 24, 2017
Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALLVirginie Nägele, Andrea Kratzer, Gerhard Zugmaier, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 19, 2003
T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody constructTorsten Dreier, Patrick A Baeuerle, Iduna Fichtner, et al.Journal for Immunotherapy of Cancer|April 24, 2025
CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activityKerry A Whalen, Catherine C Henry, Naveen K Mehta, et al.Cancer Immunology, Immunotherapy : CII|August 29, 2006
Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis modelPetra Lutterbuese, Klaus Brischwein, Robert Hofmeister, et al.Pageof 10